CRISPR, the gene-editing technology, has been one of the major breakthroughs in biology in the last two decades. And while ...

News about biofuels sometimes mentions used cooking oil as a feedstock, but if these substances contain animal fat, they can ...

CRISPR Therapeutics' (NASDAQ: CRSP) stock may be down by 21% this year so far, but that doesn't mean you should write it off ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow ...

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara co-present Dr. Jennifer Doudna, CRISPR Gene Editing and the ...

CRISPR Therapeutics has experienced a 21% decline in its stock value this year. Despite this drop, the biotech company ...

CREME is a virtual laboratory that allows scientists to simulate specific decreases in gene activity. It offers a powerful new tool for identifying and understanding important parts of the genome. And ...

The future of CRISPR involves clinical trials focused on treatment for blood diseases and cancers, cardiovascular disease, ...

With antibiotics losing their effectiveness, one company is turning to gene editing and bacteriophages—viruses that infect bacteria—to combat infections.